Mizuho Securities analyst Difei Yang assigned a Buy rating to Zogenix (NASDAQ: ZGNX) today and set a price target of $51. The company’s shares closed yesterday at $42.40, close to its 52-week high of $45.85.
“We visited clients on the west coast with Zogenix management including CEO Dr. Stephen Farr and CFO Michael Smith earlier this week. We came away feeling very positive about Study 1504 and potential pathway forward. We highlight key potential catalysts in 2018 below along with our key takeaways.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 21.0% and a 52.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Zogenix has an analyst consensus of Moderate Buy, with a price target consensus of $51.
The company has a one-year high of $45.85 and a one-year low of $10.05. Currently, Zogenix has an average volume of 483.7K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Cam Garner, a Director at ZGNX sold 218 shares for a total of $8,698.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical company, which engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. It develops two products candidate: ZX008 and Relday.